Aripiprazole is a piperazine-quinolone derivative antipsychotic research compound. It acts as a partial agonist at 5-HT1A and D2 receptors, with post-synaptic D2 antagonism and 5-HT2A receptor antagonism. This pharmacological profile makes it a key tool for in vitro and in vivo studies of schizophrenia, bipolar disorder, and neurotransmitter systems.